Jan-Niklas Eckardt, Chethan Babu V Reddy, Andrew Srisuwananukorn, Christian Pohlkamp, Maryam Schübel, Ishan Srivastava, Miriam Stoerk, Sebastian Riechert, Tim Schmittmann, Martin M K Schneider, Klaus H Metzeler, Karsten Spiekermann, Markus Badstübner, Susann Winter, Katja Sockel, Frank Kroschinsky, Christoph Röllig, Martin Bornhäuser, Tobias Herold, Torsten Haferlach, Ann-Kathrin Eisfeld, Jan Moritz Middeke
{"title":"Deep learning predicts IDH1 mutation status in acute myeloid leukemia from bone marrow smears.","authors":"Jan-Niklas Eckardt, Chethan Babu V Reddy, Andrew Srisuwananukorn, Christian Pohlkamp, Maryam Schübel, Ishan Srivastava, Miriam Stoerk, Sebastian Riechert, Tim Schmittmann, Martin M K Schneider, Klaus H Metzeler, Karsten Spiekermann, Markus Badstübner, Susann Winter, Katja Sockel, Frank Kroschinsky, Christoph Röllig, Martin Bornhäuser, Tobias Herold, Torsten Haferlach, Ann-Kathrin Eisfeld, Jan Moritz Middeke","doi":"10.1038/s41698-026-01762-x","DOIUrl":"https://doi.org/10.1038/s41698-026-01762-x","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) with IDH1 mutations is amenable to targeted therapy, highlighting the need for reliable identification. We developed an attention-based multiple-instance learning model to predict IDH1 mutation status using bone marrow smear whole-slide images from 436 AML patients across four centers in Germany and the US, achieving a mean single pooled ROC-AUC of 0.81. In top tile analysis, model predictions for IDH1 were associated with immature leukemia phenotypes.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L Gräßel, S Yacob, C Strantz, E Prochaska, T Debertshäuser, A A Rogge, S Bäcker, F Prasser, P Unberath, J Wehrle, S Jäger, M Boerries, A L Illert, U Lührig, M Wolfien
{"title":"The promise and limits of patient-reported outcomes in molecular tumor board-guided care: toward a framework for patient-centered precision oncology.","authors":"L Gräßel, S Yacob, C Strantz, E Prochaska, T Debertshäuser, A A Rogge, S Bäcker, F Prasser, P Unberath, J Wehrle, S Jäger, M Boerries, A L Illert, U Lührig, M Wolfien","doi":"10.1038/s41698-026-01719-0","DOIUrl":"https://doi.org/10.1038/s41698-026-01719-0","url":null,"abstract":"<p><p>Patient-reported outcomes (PROs) capture symptoms, functioning, quality of life, treatment burden and priorities directly from patients. Their integration into Molecular Tumor Board (MTB)-guided care remains limited and particularly challenging, as recommendations often involve off-label therapies, sparse evidence and complex benefit-burden trade-offs. In this perspective, we propose a four-domain framework encompassing measurement, data integration, decision support and governance to guide longitudinal monitoring and patient-centered learning.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Taofang Cheng, Huiqun Wu, Rui Jing, Yue Li, Rong Wei
{"title":"Single-cell analysis reveals favorable responses of tumor-associated monocytes to bortezomib-based treatment in multiple myeloma.","authors":"Taofang Cheng, Huiqun Wu, Rui Jing, Yue Li, Rong Wei","doi":"10.1038/s41698-026-01666-w","DOIUrl":"https://doi.org/10.1038/s41698-026-01666-w","url":null,"abstract":"<p><p>The bone marrow microenvironment (BME) has a significant effect on bortezomib (BTZ)-based chemotherapy in patients with multiple myeloma (MM). However, how BME components drive effective BTZ-based chemotherapy to facilitate antitumor responses has yet to be fully understood. Using single-cell transcriptome analysis, we discerned a notable increase in the density of tumor-associated IL1B<sup>+</sup> monocytes (TAMO_IL1B), a CD14<sup>+</sup> monocyte subcluster, within the optimal responders (OR) group compared with the suboptimal responders (SOR) group. TAMO_IL1B in the OR group had significantly greater effects on the TGF-β signaling pathway. The ligand-receptor pair (THBS1-SDC1) interaction intensity in the THBS1 signaling pathway between TAMO_IL1B and tumor plasma cells (TPC) in the OR group was significantly greater than that in the SOR group. Furthermore, pseudotime trajectory analysis indicated that TAMO_IL1B predominantly occupied late differentiation stages and was associated with a favorable response within the OR group. These findings reveal a previously unrecognized role for TAMO_IL1B in shaping antitumor immunity. The THBS1-SDC1 axis may contribute to interactions between monocytes and plasma cells; however, functional validation is required before any therapeutic implications can be drawn.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T Lowinus, V Schipperges, P Metzger, T Brummer, U Matysiak, E P Dopfer, M E Hess, M Fahrner, T Pauli, A Blaumeiser, H Becker, J Kuehn, M Rassner, J Falkenstein, H Bertemes, P Bovio, N Pinter, S Cysar, S Lehr, R Wäsch, L Gräßel, K Eyerich, A M Schultheis, O Schilling, S Lassmann, M Werner, A L Illert, J Duyster, R Zeiser, C C Miething, M Boerries, F Meiss, D Rafei
{"title":"Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg.","authors":"T Lowinus, V Schipperges, P Metzger, T Brummer, U Matysiak, E P Dopfer, M E Hess, M Fahrner, T Pauli, A Blaumeiser, H Becker, J Kuehn, M Rassner, J Falkenstein, H Bertemes, P Bovio, N Pinter, S Cysar, S Lehr, R Wäsch, L Gräßel, K Eyerich, A M Schultheis, O Schilling, S Lassmann, M Werner, A L Illert, J Duyster, R Zeiser, C C Miething, M Boerries, F Meiss, D Rafei","doi":"10.1038/s41698-026-01763-w","DOIUrl":"10.1038/s41698-026-01763-w","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) and BRAF/MEK kinase inhibitors have substantially improved survival in advanced melanoma; however, therapeutic resistance and severe toxicities underscore the ongoing need for alternative strategies. Here, we evaluate the clinical utility of multi-omic profiling, biomarker-stratified recommendations, and survival outcomes within a prospective cohort of 98 patients with advanced cutaneous or uveal melanoma evaluated by the Molecular Tumor Board Freiburg (MTB-FR) between 2021 and 2024. Completed profiling revealed at least one potential actionable target beyond classical BRAF V600 mutations in 83.8% of cases. Alterations in NRAS, atypical BRAF variants, CDK4/6 pathway amplifications, and DNA-damage response (DDR) gene mutations most frequently guided board recommendations. Biomarker-stratified therapies were recommended for 68.4% of patients, and personalized immunotherapy combinations for 72.4%. The treatment implementation rate was 33.8% (n = 27), achieving an overall disease control rate (DCR) of 42.9% and an overall response rate (ORR) of 10.7%. These findings demonstrate that comprehensive molecular profiling in a real-world setting uncovers actionable alterations, providing viable subsequent treatment avenues that may optimize outcomes for heavily pretreated melanoma patients beyond established standards of care. Ultimately, prospective, randomized, biomarker-driven trials remain essential to validate whether these individualized diagnostic strategies translate into a reproducible survival benefit.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149238904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdelrahman M Elsayed, Yuwaraj Kadariya, Lindsey Byrne, Eleonora Sementino, Leigha Senter, Isabella Gray, Olivia Taylor, Asmaa Mosbeh, Naomi Canny, Ying L Liu, Christa I Nagel, Joseph McElroy, Rania Sheikh, Colleen M Cebulla, Maria I Carlo, Mohamed H Abdel-Rahman, Joseph R Testa
{"title":"Ovarian sex cord-stromal tumors are part of the BAP1-tumor predisposition syndrome: evidence from human carriers and mouse models.","authors":"Abdelrahman M Elsayed, Yuwaraj Kadariya, Lindsey Byrne, Eleonora Sementino, Leigha Senter, Isabella Gray, Olivia Taylor, Asmaa Mosbeh, Naomi Canny, Ying L Liu, Christa I Nagel, Joseph McElroy, Rania Sheikh, Colleen M Cebulla, Maria I Carlo, Mohamed H Abdel-Rahman, Joseph R Testa","doi":"10.1038/s41698-026-01741-2","DOIUrl":"https://doi.org/10.1038/s41698-026-01741-2","url":null,"abstract":"<p><p>Germline heterozygous BAP1 pathogenic/likely pathogenic (P/LP) variants are associated with the BAP1-tumor predisposition syndrome (BAP1-TPDS). This study evaluated evidence for an association between ovarian cancers and BAP1-TPDS. We evaluated ovarian cancer incidence in two independent cohorts of female subjects with germline BAP1 P/LP variants. Additionally, we investigated whether the high incidence of spontaneous ovarian sex cord-stromal tumors (OSCSTs) in heterozygous Bap1-mutant FVB/N mice was strain-specific by examining their occurrence in several other Bap1-mutant mouse models with different genetic backgrounds. In the combined human cohort of 176 females with BAP1 P/LP variants, 7 (4%) had ovarian cancer, including 3 with OSCST. Another OSCST occurred in a patient with a germline BAP1 variant with conflicting pathogenesis, for which functional studies supported pathogenicity. OSCSTs were observed in all mouse strains with germline heterozygous Bap1 mutations (incidence: 32%-73%). Biallelic inactivation of BAP1 was observed in 3/3 human and 10/10 murine OSCSTs. OSCSTs from Bap1-mutant mice showed marked decreases in Bmpr1b, Erb, and Foxl2 expression, suggesting disruption of pathways involved in ovarian differentiation and homeostasis. In conclusion, ovarian cancers, particularly OSCSTs, represent a rarer phenotype of the BAP1-TPDS. Downregulation of Bmpr1b, Erb, and Foxl2 may reflect alterations in pathways amenable to therapeutic targeting in OSCSTs.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Irina A Kerle, Oleksandr Husak, Thomas Gross, Andreas Hartig, Rebecca Prause, Daniela Richter, Sascha Brückmann, Maximilian Werner, Anja Kögler, Dorothea Hanf, Lino Möhrmann, Doreen William, Karsten Wendt, Nicole Pfarr, Carolin Mogler, Daniela E Aust, Evelin Schröck, Christoph Heining, Hanno Glimm
{"title":"Machine learning uncovers previously undetectable genetic deletions in cancer panel sequencing.","authors":"Irina A Kerle, Oleksandr Husak, Thomas Gross, Andreas Hartig, Rebecca Prause, Daniela Richter, Sascha Brückmann, Maximilian Werner, Anja Kögler, Dorothea Hanf, Lino Möhrmann, Doreen William, Karsten Wendt, Nicole Pfarr, Carolin Mogler, Daniela E Aust, Evelin Schröck, Christoph Heining, Hanno Glimm","doi":"10.1038/s41698-026-01756-9","DOIUrl":"10.1038/s41698-026-01756-9","url":null,"abstract":"<p><p>Missed genetic deletions can prevent cancer patients from receiving effective targeted therapy. Standard pipelines, such as TSO500, use bin count averaging for copy number variation detection but often overlook focal events. To address this, we developed a machine learning (ML) pipeline for deletion detection and zygosity evaluation within the MASTERsg precision oncology program. We focused on the tumor suppressor gene PTEN, whose loss confers sensitivity to mTOR/Akt inhibition. An Extreme Gradient Boosting model trained on PTEN-deleted and wild-type tumor samples identified focal deletions missed by the TSO500 pipeline and CNVkit that were associated with concordant PTEN protein loss by immunohistochemistry. Importantly, the model detected PTEN deletions in 33/204 profiled samples that were classified as PTEN wild-type by TSO500; 75% (15/20) of stainable cases showed absent or reduced PTEN protein expression. These findings demonstrate the potential of ML to enhance panel sequencing, uncovering therapeutically relevant alterations missed by established diagnostic methods.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149207475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xuekang Qi, Georgios Mermelekas, Ondrej Hodek, Luay Aswad, Quentin Glaziou, Isabelle Rose Leo, Nona Struyf, Femke M Hormann, Ioannis Siavelis, Henri Colyn Bwanika, Owen F J Hovey, Martin Haraldsson, Sean G Rudd, Annika I Johansson, Tom Erkers, Katja Pokrovskaja Tamm, Janne Lehtiö, Rozbeh Jafari
{"title":"Multi-omics profiling identifies triciribine as a biomarker-guided antimetabolite therapy for acute lymphoblastic leukemia.","authors":"Xuekang Qi, Georgios Mermelekas, Ondrej Hodek, Luay Aswad, Quentin Glaziou, Isabelle Rose Leo, Nona Struyf, Femke M Hormann, Ioannis Siavelis, Henri Colyn Bwanika, Owen F J Hovey, Martin Haraldsson, Sean G Rudd, Annika I Johansson, Tom Erkers, Katja Pokrovskaja Tamm, Janne Lehtiö, Rozbeh Jafari","doi":"10.1038/s41698-026-01736-z","DOIUrl":"10.1038/s41698-026-01736-z","url":null,"abstract":"<p><p>Acute lymphoblastic leukemia (ALL) exhibits molecular and metabolic heterogeneity that limits therapeutic efficacy. Although antimetabolites remain central to ALL treatment, determinants of therapeutic sensitivity and resistance remain incompletely understood. Here, we investigated the activity and molecular response landscape of the purine analog triciribine (TCN) across diverse ALL models using integrated phosphoproteomics, thermal proteome profiling, and quantitative proteomics. TCN showed potent cytotoxicity across ALL cell lines and a drug response profile distinct from canonical PI3K-Akt-mTOR inhibitors. Early phosphoproteomics revealed no consistent suppression of Akt pathway signaling, with transient activation of several Akt-associated readouts and inhibition of cyclin-dependent kinase signaling. The monophosphorylated metabolite TCN-P was the predominant intracellular active species, and adenosine kinase (ADK) was required for TCN-P generation and cytotoxicity. Proteome Integral Solubility Alteration profiling identified candidate TCN-P interactions involving nucleotide metabolism, DNA replication, and protein synthesis, associated with impaired purine biosynthesis, DNA damage, translational stress, and cell-cycle perturbation. Across ALL cell lines and primary samples, ADK levels correlated positively with TCN sensitivity, supporting ADK-dependent metabolism as a major determinant of therapeutic response. Together, these findings identify TCN as a metabolically activated antileukemic agent with broad antimetabolite activity and nominate ADK as a potential predictive biomarker for precision therapy in ALL.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Johannes Moll, Jannik Lübberstedt, Christoph Nuernbergk, Jacob Stroh, Luisa Mertens, Anna Purcarea, Christopher Zirn, Zeineb Benchaaben, Fabian Drexel, Hartmut Häntze, Anirudh Narayanan, Friedrich Puttkammer, Andrei Zhukov, Jacqueline Lammert, Sebastian Ziegelmayer, Markus Graf, Marion Högner, Marcus Makowski, Florian Bassermann, Lisa C Adams, Jiazhen Pan, Daniel Rueckert, Krischan Braitsch, Keno K Bressem
{"title":"Skill-guided agentic reasoning enables longitudinal synthesis of myeloma records at expert-level concordance.","authors":"Johannes Moll, Jannik Lübberstedt, Christoph Nuernbergk, Jacob Stroh, Luisa Mertens, Anna Purcarea, Christopher Zirn, Zeineb Benchaaben, Fabian Drexel, Hartmut Häntze, Anirudh Narayanan, Friedrich Puttkammer, Andrei Zhukov, Jacqueline Lammert, Sebastian Ziegelmayer, Markus Graf, Marion Högner, Marcus Makowski, Florian Bassermann, Lisa C Adams, Jiazhen Pan, Daniel Rueckert, Krischan Braitsch, Keno K Bressem","doi":"10.1038/s41698-026-01733-2","DOIUrl":"10.1038/s41698-026-01733-2","url":null,"abstract":"<p><p>Patients with multiple myeloma accumulate hundreds of clinical documents over years of sequential therapy, and every treatment decision depends on synthesis across that history. Whether large language model-based systems can match expert agreement on this task, and where they fail, has not been established. On longitudinal records of 811 patients treated over 25 years (44,962 documents and 1,334,677 laboratory values), an agentic reasoning system guided by an indexed clinical skill library was compared against single-pass retrieval-augmented generation (RAG), iterative RAG, iterative RAG augmented with the same skill library, and full-context input on 469 expert-adjudicated patient-question pairs, with an exploratory cross-dataset evaluation on MIMIC-IV. The skill-guided agent exceeded the ceiling at which iterative RAG (75.7%) and full-context input (75.8%) converged, reaching 80.1% concordance, with its advantage widening on the most complex tasks (+11.2 percentage points) and longest records. Providing the same skill library to iterative RAG matched the agent in aggregate (79.0%) and on shorter records, whereas the agent retained a significant advantage on the longest records (+10.3 percentage points in the top decile, p = 0.017) and a numerical, non-significant advantage on the most complex questions (+5.4 percentage points). The aggregate error rate (12.2%) was comparable to expert disagreement (13.6%), but a higher proportion of system errors were clinically significant (57.8 versus 18.8%).</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Razan Zuhair, Mark Eastwood, Megan Bradbury, Amy Cross, Joanna Hester, Fadi Issa, Fiona Ginty, Heba Z Sailem
{"title":"Decoding spatial mTOR signalling reveals distinct roles in the tumour microenvironment.","authors":"Razan Zuhair, Mark Eastwood, Megan Bradbury, Amy Cross, Joanna Hester, Fadi Issa, Fiona Ginty, Heba Z Sailem","doi":"10.1038/s41698-026-01674-w","DOIUrl":"10.1038/s41698-026-01674-w","url":null,"abstract":"<p><p>The tumour microenvironment comprises a variety of cell types that interact with malignant cells, influencing both cancer progression and the patient response to therapy. Given the intricate interactions among these components, assessing how signalling pathways contribute to cancer progression by acting on different components of the TME is particularly complex. Multiplexed imaging allows simultaneous assessment of signalling in multiple of these components. Here, we utilise a highly multiplexed dataset of 61 markers across 746 colorectal tumours to investigate how complex mTOR signalling in different tissue compartments influences patient prognosis. We found that mTOR pathway signalling in immune cells correlates with favourable patient survival. Advanced spatially-aware analysis of signalling activities using graph neural networks revealed that the positive association between immune mTOR signalling and patient survival was more pronounced in tumours with features of a more differentiated morphology. Integrative analysis using TCGA data and spatial transcriptomics confirmed a role for immune mTOR signalling in immune activation, accompanied by reduced TGF-β signalling. Our work highlights the importance of adopting a personalised approach to targeting mTOR in cancer patients and establishes a framework for studying cell type-specific signalling in the TME.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"10 1","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
